Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott North

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Current Oncology (Toronto, Ont.)|September 27, 2024
Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate CancerGabrielle Robin, Naveen S Basappa, Scott North, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 28, 2018
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancerAlisha Shivji, Raafi Ali, Scott North, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 29, 2017
The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trialErin L McGowan, Daniel Fuller, Nicoleta Cutumisu, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 11, 2017
High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinomaSeyyed Mohammad Reza Kazemi-Bajestani, Harald Becher, Peter Venner, et al.
The International Journal of Behavioral Nutrition and Physical Activity|August 8, 2012
Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behaviorLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Psycho-Oncology|January 29, 2015
Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot studyLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 28, 2011
Physical activity preferences in a population-based sample of kidney cancer survivorsLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Cancer Nursing|November 16, 2013
Feasibility and preliminary efficacy of adding behavioral counseling to supervised physical activity in kidney cancer survivors: a randomized controlled trialLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 7, 2011
Associations between physical activity and quality of life in a population-based sample of kidney cancer survivorsLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Journal of Medical Economics|April 26, 2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in CanadaFred Saad, Andrew Chilelli, Benny Hui, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Current Oncology (Toronto, Ont.)|September 27, 2024
Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate CancerGabrielle Robin, Naveen S Basappa, Scott North, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 28, 2018
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancerAlisha Shivji, Raafi Ali, Scott North, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 29, 2017
The role of the built environment in a randomized controlled trial to increase physical activity among men with prostate cancer: the PROMOTE trialErin L McGowan, Daniel Fuller, Nicoleta Cutumisu, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 11, 2017
High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinomaSeyyed Mohammad Reza Kazemi-Bajestani, Harald Becher, Peter Venner, et al.
The International Journal of Behavioral Nutrition and Physical Activity|August 8, 2012
Correlates of physical activity in a population-based sample of kidney cancer survivors: an application of the theory of planned behaviorLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Psycho-Oncology|January 29, 2015
Changes in motivational outcomes following a supervised physical activity program with behavioral counseling in kidney cancer survivors: a pilot studyLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 28, 2011
Physical activity preferences in a population-based sample of kidney cancer survivorsLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Cancer Nursing|November 16, 2013
Feasibility and preliminary efficacy of adding behavioral counseling to supervised physical activity in kidney cancer survivors: a randomized controlled trialLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 7, 2011
Associations between physical activity and quality of life in a population-based sample of kidney cancer survivorsLinda Trinh, Ronald C Plotnikoff, Ryan E Rhodes, et al.
Journal of Medical Economics|April 26, 2022
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in CanadaFred Saad, Andrew Chilelli, Benny Hui, et al.
Pageof 10